Last reviewed · How we verify
NCT04926493: BIOPAVIR
Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Patients at Increased Risk for the Development of Ventilator-associated Pneumonia in the Intensive Care Unit
trial testing microbiological characterization in Biofilm Formation in 61 participants. Completed in 31 July 2021.
31 July 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 61 |
| Start date | 1 May 2021 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- microbiological characterization — full drug profile →
Conditions studied
- Biofilm Formation — all drugs for Biofilm Formation →
- Structural and Microbiological Characterization of Endotracheal Tube Biofilm — all drugs for Structural and Microbiological Characterization of Endotracheal Tube Biofilm →
- Ventilator-associated Pneumonia (VAP) — all drugs for Ventilator-associated Pneumonia (VAP) →
Sponsor
Centre Hospitalier Universitaire Dijon
Who can join
18 and older, any sex, with Biofilm Formation or Structural and Microbiological Characterization of Endotracheal Tube Biofilm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ventilator-associated pneumonia (VAP) remains the most frequent healthcare-associated infection (HAI) in the intensive care unit (ICU) and one of the most critical risk factors associated with both significant morbidity as well as mortality. Although VAP treatment relies on early and appropriate antimicrobial therapy, several preventive measures have been described in the literature in order to limit its incidence and clinical impact in the ICU. Among these, preventing biofilm formation on the inner surface of the endotracheal tube appears to hold promise. Yet there is a lack of clinical relevant data documenting a causal relation between biofilm formation and VAP. Designed to overcome this critical limitation, the BIOPAVIR study intends to provide a better structural and microbiological characterization of endotracheal tube biofilm in critically ill patients at increased risk for the development of VAP in ICU during COVID-19 pandemic.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Endotracheal tube biofilm in critically ill patients during the COVID-19 pandemic : description of an underestimated microbiological compartment.
Maldiney T, Pineau V, Neuwirth C, Ouzen L, et al · · 2022 · cited 7× · PMID 36575298 · DOI 10.1038/s41598-022-26560-w
Verify or expand the search:
- PubMed search for NCT04926493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire Dijon trials
Trials by the same sponsor.
- NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
- NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
- NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
- NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
- NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04926493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing